Nyxoah Details Early U.S. Genio Launch, Reimbursement Update at Oppenheimer MedTech Conference 2026

5 hours ago 1

MarketBeat

Sat, March 21, 2026 astatine 7:07 AM CDT 7 min read

Nyxoah logo

Nyxoah's U.S. motorboat is underway targeting ~400 high‑volume sites; the institution covered 125 people accounts early, secured >70 VAC approvals with progressive implants astatine 50+ accounts, and reported $4.5 million of U.S. gross successful Q4 with absorption forecasting beardown double‑digit growth.
The Genio strategy differentiates via minimally invasive, single‑incision, battery‑free bilateral stimulation and an “implant for life” statement (12‑year longevity); pivotal DREAM information showed a 63.5% AHI responder complaint and beardown supine show with 82% of implanted patients achieving AHI <15 astatine 12 months.
Reimbursement is mostly intact—commercial payers relationship for >90% of existent business—and CMS mapped some technologies to APC level 5 with a installation interest of $31,526; Nyxoah targets profitability astatine astir EUR 150 million gross assuming >80% gross margins, aided by outgo reductions similar a caller activation chip.
Interested successful Nyxoah SA? Here are 5 stocks we similar better.

Nyxoah (NASDAQ:NYXH) utilized its presumption astatine Oppenheimer’s MedTech and Services Conference 2026 to outline the company’s aboriginal U.S. motorboat advancement for its Genio system, a neuromodulation therapy for obstructive slumber apnea (OSA), and to code capitalist questions astir reimbursement and operating leverage.

Management described the U.S. OSA accidental arsenic “roughly” a $10 cardinal marketplace and said it remains highly underpenetrated. Nyxoah emphasized that it is present an progressive U.S. marketplace subordinate pursuing FDA support successful August of past year, positioning Genio arsenic a 2nd enactment alongside the existing unilateral hypoglossal nervus stimulation approach.

→ Forget Chipmakers: Walmart and Target Are the Real AI Plays

The institution reviewed the objective rationale for OSA treatment, noting that repeated nightly airway obstructions tin pb to oxygen deprivation and are associated with accrued risks of cardiovascular disease, stroke, and bosom failure. Nyxoah said it is focused connected mean to terrible OSA, which it defined arsenic patients experiencing astatine slightest 15 obstructions per hour, up to 65 per hr for precise terrible cases.

Nyxoah characterized Genio arsenic differentiated from a pacemaker-style system, emphasizing a minimally invasive, single-incision implant nether the chin with nary implanted battery. The institution said Genio provides bilateral stimulation, which it believes enables stronger airway opening and whitethorn assistance code much analyzable obstructions.

Read Entire Article